Market revenue in 2023 | USD 46.3 million |
Market revenue in 2030 | USD 66.8 million |
Growth rate | 5.4% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 66.31% in 2023. Horizon Databook has segmented the Mexico neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is an attractive destination for outsourcing clinical trials as cost plays a major factor. Moreover, proximity to the U.S. and availability of investigators in urban areas also help in cost-cutting. As the population in the country cannot afford treatment of chronic diseases, they usually prefer participating in such trials.
Hence, availability of a diverse patient pool is one of the factors driving the market. The establishment of a regulatory entity—Federal Commission for the Protection against Sanitary Risk (COFEPRIS)—and shortening of setup time for clinical trials to two months have also attracted many clients.
In addition, there is high investment in infrastructure development to provide better facilities. Mexico’s largest hospital chain has invested around USD 700 million to build 15 new hospitals to encourage clinical trials and medical tourism. Such factors are likely to promote the neurology clinical trials market in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Mexico neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account